Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease

被引:17
作者
Serra, Andreas L. [1 ,2 ,3 ]
Kistler, Andreas D. [1 ]
Poster, Diane [1 ]
Krauer, Fabienne [1 ]
Senn, Oliver [4 ]
Raina, Shagun [2 ,3 ]
Pavik, Ivana [2 ,3 ]
Rentsch, Katharina [5 ]
Regeniter, Axel [6 ]
Weishaupt, Dominik [7 ]
Wuethrich, Rudolf P. [1 ,2 ,3 ]
机构
[1] Univ Zurich Hosp, Div Nephrol, Zurich, Switzerland
[2] Univ Zurich, Inst Physiol, CH-8006 Zurich, Switzerland
[3] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8006 Zurich, Switzerland
[4] Univ Zurich, Inst Gen Practice & Hlth Serv Res, CH-8006 Zurich, Switzerland
[5] Univ Zurich Hosp, Inst Clin Chem, Zurich, Switzerland
[6] Univ Basel Hosp, Lab Med, Basel, Switzerland
[7] Univ Zurich Hosp, Div Diagnost Radiol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
autosomal dominant polycystic kidney disease (ADPKD); safety; sirolimus; treatment adherence; urinary protein profile; RENAL-TRANSPLANT RECIPIENTS; EIF2-ALPHA KINASE GCN2; CALCINEURIN INHIBITORS; ALLOGRAFT-REJECTION; IRON HOMEOSTASIS; MDI-LABLINK; PROTEINURIA; PROGRESSION; EVEROLIMUS; VOLUME;
D O I
10.1093/ndt/gfp280
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. We initiated a randomized controlled clinical trial to assess the effect of sirolimus on disease progression in patients affected by autosomal dominant polycystic kidney disease (ADPKD). Here we report the preliminary safety results of the first 6 months of treatment. Method. A total of 25 patients were randomized to sirolimus 2 mg/day and 25 patients to no treatment except standard care. Treatment adherence was monitored electronically. At baseline and at Month 6, laboratory parameters were analysed and the urinary protein profile in 24-h urine collections was determined. Results. Both treatment groups were well balanced for age, sex and renal function. In 94.1 +/- 11.4% of the study days, patients in the sirolimus group were exposed to the drug when assuming a therapeutic efficacy duration of 30 h. At Month 6, the mean sirolimus dose and trough level were 1.28 +/- 0.71 mg/day and 3.8 +/- 1.9 mu g/l, respectively. Glomerular (albumin, transferrin, IgG) and tubular (retinol-binding protein, alpha(1)-microglobulin) protein excretion remained unchanged. Glomerular filtration rate also did not change significantly. Haematological parameters were similar in both groups, except for a mild reduction of the mean corpuscular volume of erythrocytes in patients receiving sirolimus. Lipid levels were similar in both groups. Adverse events were transient and mild, and no grade 3 or 4 events occurred. The incidence of infections was similar in the sirolimus group (80%) and the standard group (88%). The most common gastrointestinal adverse events were mucositis (72% in the sirolimus group versus 16% in the standard group, P = 0.0001) and diarrhoea (36% in the sirolimus versus 20% in the standard group, P = 0.345). Conclusion. Treatment of ADPKD patients with sirolimus with a dose of 1-2 mg/day is safe and does not cause proteinuria or impairment of GFR. Treatment adherence was excellent. (ClinicalTrials.gov number, NCT00346918.)
引用
收藏
页码:3334 / 3342
页数:9
相关论文
共 34 条
[1]   Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue [J].
Butani, L .
TRANSPLANTATION, 2004, 78 (09) :1362-1366
[2]   Early experience with sirolimus in lung transplant recipients with chronic allograft rejection [J].
Cahill, BC ;
Somerville, KT ;
Crompton, JA ;
Parker, ST ;
O'Rourke, MK ;
Stringham, JC ;
Karwande, SV .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (02) :169-176
[3]   Translational control by TOR and TAP42 through dephosphorylation of eIF2α kinase GCN2 [J].
Cherkasova, VA ;
Hinnebusch, AG .
GENES & DEVELOPMENT, 2003, 17 (07) :859-872
[4]   Pathophysiology of proteinuria [J].
D'Amico, G ;
Bazzi, C .
KIDNEY INTERNATIONAL, 2003, 63 (03) :809-825
[5]  
DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1
[6]   Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice [J].
Farmer, KC .
CLINICAL THERAPEUTICS, 1999, 21 (06) :1074-1090
[7]   Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients [J].
Fructuoso, A. Sanchez ;
Calvo, N. ;
Moreno, M. A. ;
Giorgi, M. ;
Barrientos, A. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) :2242-2244
[8]   Volume progression in polycystic kidney disease [J].
Grantham, JJ ;
Torres, VE ;
Chapman, AB ;
Guay-Woodford, LM ;
Bae, KT ;
King, BF ;
Wetzel, LH ;
Baumgarten, DA ;
Kenney, PJ ;
Harris, PC ;
Klahr, S ;
Bennett, WM ;
Hirschman, GN ;
Meyers, CM ;
Zhang, XL ;
Zhu, F ;
Miller, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2122-2130
[9]   Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients [J].
Hoogeveen, RC ;
Ballantyne, CM ;
Pownall, HJ ;
Opekun, AR ;
Hachey, DL ;
Jaffe, JS ;
Oppermann, S ;
Kahan, BD ;
Morrisett, JD .
TRANSPLANTATION, 2001, 72 (07) :1244-1250
[10]   Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study [J].
Kahan, BD .
LANCET, 2000, 356 (9225) :194-202